share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP：信函
美股SEC公告 ·  07/16 12:40
Moomoo AI 已提取核心訊息
60 Degrees Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed under File No. 333-280796. The company, headquartered in Washington, D.C., seeks to have the Registration Statement become effective at 9:00 a.m. Eastern Time on July 18, 2024, or as soon thereafter as practicable. This request, made pursuant to Rule 461 of the Securities Act of 1933, comes with the acknowledgment from the company that the SEC's declaration of effectiveness does not preclude further SEC action regarding the Registration Statement, nor does it absolve the company of its responsibility for the adequacy of the disclosure within the Registration Statement. The company also recognizes that it cannot use the SEC's comments or the effectiveness of the Registration Statement as a defense in any legal proceedings. Upon effectiveness, 60 Degrees Pharmaceuticals has requested oral confirmation from the SEC and a written order verifying the effective time and date to be sent to their counsel, Sichenzia Ross Ference Carmel LLP.
60 Degrees Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed under File No. 333-280796. The company, headquartered in Washington, D.C., seeks to have the Registration Statement become effective at 9:00 a.m. Eastern Time on July 18, 2024, or as soon thereafter as practicable. This request, made pursuant to Rule 461 of the Securities Act of 1933, comes with the acknowledgment from the company that the SEC's declaration of effectiveness does not preclude further SEC action regarding the Registration Statement, nor does it absolve the company of its responsibility for the adequacy of the disclosure within the Registration Statement. The company also recognizes that it cannot use the SEC's comments or the effectiveness of the Registration Statement as a defense in any legal proceedings. Upon effectiveness, 60 Degrees Pharmaceuticals has requested oral confirmation from the SEC and a written order verifying the effective time and date to be sent to their counsel, Sichenzia Ross Ference Carmel LLP.
60 Degrees Pharmaceuticals已正式向美國證券交易委員會（SEC）提出請求，加速其在文件編號333-280796下最初提交的S-3表格的註冊聲明生效日期。總部位於華盛頓特區的公司希望該註冊聲明在2024年7月18日東部時間上午9:00生效，或儘快在此之後。根據1933年證券法規461條的規定，此要求是在公司承認SEC的生效聲明不會排除就註冊聲明進一步採取行動，也不會免除該公司對註冊聲明中披露充分性的責任的情況下提出的。該公司還認識到，它不能在任何法律程序中使用SEC的評論或註冊聲明的效力作爲辯護。在生效後，60 Degrees Pharmaceuticals已要求SEC口頭確認，併發送一份書面命令，以核實有效的時間和日期，發送給他們的律師團隊Sichenzia Ross Ference Carmel LLP。
60 Degrees Pharmaceuticals已正式向美國證券交易委員會（SEC）提出請求，加速其在文件編號333-280796下最初提交的S-3表格的註冊聲明生效日期。總部位於華盛頓特區的公司希望該註冊聲明在2024年7月18日東部時間上午9:00生效，或儘快在此之後。根據1933年證券法規461條的規定，此要求是在公司承認SEC的生效聲明不會排除就註冊聲明進一步採取行動，也不會免除該公司對註冊聲明中披露充分性的責任的情況下提出的。該公司還認識到，它不能在任何法律程序中使用SEC的評論或註冊聲明的效力作爲辯護。在生效後，60 Degrees Pharmaceuticals已要求SEC口頭確認，併發送一份書面命令，以核實有效的時間和日期，發送給他們的律師團隊Sichenzia Ross Ference Carmel LLP。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息